What it is

Teduglutide is a glucagon-like peptide-2 (GLP-2) analog used in the management of short bowel syndrome (SBS) with intestinal failure.

The core clinical goal is to improve intestinal absorption enough to reduce the amount of parenteral support (IV fluids and nutrition) a patient needs.

Why people care

SBS can be life-altering. Parenteral support can be essential, but it also increases burden and risks (catheter infections, liver complications, hydration instability).

A peptide therapy that reliably reduces parenteral needs can translate into meaningful quality-of-life improvements.

How it works (high level)

GLP-2 is an endogenous gut hormone involved in intestinal growth and adaptation.

Teduglutide is designed to activate GLP-2 pathways that support:

mucosal growth and intestinal adaptation
improved absorptive capacity
reduced stool or stoma output in some settings

Evidence landscape

Teduglutide is part of the established, clinically used SBS pharmacology landscape.

However, the size of benefit varies across patients and depends on anatomy, remaining bowel length, colon continuity, baseline parenteral needs, and clinical management.

Latest updates

2026-03-23: A clinical review summarized recent evidence and real-world experience with GLP-1 and GLP-2 agonists in SBS, with attention to side effects (GI symptoms, fluid balance issues, gallbladder events, injection-site reactions) and newer long-acting GLP-2 candidates.
- PubMed: https://pubmed.ncbi.nlm.nih.gov/41866997/

Safety reality

In SBS, “typical” side effects can become clinically important. Monitoring often focuses on:

fluid balance and edema
abdominal symptoms
biliary events (gallbladder)
injection-site reactions

This page is informational and does not substitute for medical advice.

References

Gorard L, et al. Glucagon-like peptide agonists and use in short bowel syndrome: what about the side effects? Curr Opin Gastroenterol. (2026). https://pubmed.ncbi.nlm.nih.gov/41866997/